By analyzing E. coli protein levels, scientists found a surplus of membrane shuttle proteins that may play a role in antibiotic resistance.

Cornell researchers have identified a key protein mechanism that helps bacteria expel antibiotics, making them more resistant ...

A Cornell University-led collaboration has uncovered the equipment that enables bacteria to survive exposure to antibiotics: ...

The Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome are collaborating on a $50 million effort to boost ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Research into developing new antimicrobial resistance treatment in Nigeria and other low/middle-income countries has fuelled ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...